Dissemin is shutting down on January 1st, 2025

Published in

Wiley, European Journal of Haematology, 6(99), p. 553-558, 2017

DOI: 10.1111/ejh.12973

Links

Tools

Export citation

Search in Google Scholar

Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.

Journal article published in 2017 by Paul J. Bröckelmann, Erin A. Zagadailov, Shelby L. Corman ORCID, Viktor Chirikov, Courtney Johnson, Cynthia Macahilig, Brian Seal, Mehul R. Dalal, Timothy M. Illidge ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Lymphoma Research Team ; Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multiagent chemotherapy is not an option. The objective of this study was to describe real-world outcomes with BV in patients with rrHL considered ASCT ineligible or who refuse ASCT.